Nordic Stocks: Danske Bank, Diamyd Medical, Eitzen Shares Move

The Stoxx Nordic 30 Index, the benchmark measure for the region, slipped 0.2 percent to 7,697.36 at the 5:30 p.m. close in Stockholm, a third straight day of losses.

The OMX Stockholm 30 Index (OMX) slid 0.3 percent. The OMX Helsinki 25 Index (HEX25) declined 0.4 percent, while Norway’s OBX Index fell 0.8 percent. The Copenhagen 20 Index (KFX) dropped less than 0.1 percent.

Danske Bank A/S (DANSKE) lost 1.7 percent to 136.40 kroner. Denmark’s largest lender does not plan to buy assets from Allied Irish Banks Plc in Northern Ireland, Anders Klinkby Madsen, a Danske Bank spokesman, said by phone today.

The U.K.’s Sunday Times newspaper reported yesterday that Danske Bank may be interested in buying Allied’s Northern Irish business, without citing anyone.

Diamyd Medical AB (DIAMB) gained 2.4 percent to 136.25 kronor. The Swedish biotechnology company dosed the first subject in a Phase II clinical trial in the U.S. evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.

Eitzen Chemical ASA (ECHEM) plunged 19 percent to 1.35 kroner, the biggest drop in almost two years. The Norwegian chemical-tanker owner said trading in the fourth quarter of 2010 was weaker than forecast, mainly because of lower activity in regional trades.

Nokian Renkaat Oyj (NRE1V) (NRE1V FH) surged 2.5 percent to 28.40 euros after the Nordic region’s biggest tiremaker said full-year sales and operating profit for 2010 were better than expected.

Prosafe SE (PRS) slipped 0.7 percent to 44.70 kroner as Fondsfinans downgraded the stock to “sell” from “neutral’.

Telenor ASA (TEL) , the Nordic region’s largest telephone company, declined 1.9 percent to 91 kroner after Goldman Sachs Group Inc. removed the stock from its “conviction buy” list.

To contact the reporter on this story: Giles Broom in Zurich at gbroom@bloomberg.net.

To contact the editor responsible for this story: David Merritt at dmerritt1@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.